Bringing Ibrutinib To The Frontline Of Chronic Gvhd Treatment

Bringing ibrutinib to the frontline of chronic GvHD treatment

VJHemOnc – Video Journal of Hematology & HemOnc

Ibrutinib for treating chronic GvHD

VJHemOnc – Video Journal of Hematology & HemOnc

Ruxolitinib and ibrutinib: the future for GvHD treatment?

VJHemOnc – Video Journal of Hematology & HemOnc

David Miklos, MD, PhD: Ibrutinib in Chronic Graft-Versus-Host Disease

American Society of Hematology

Ibrutinib to Treat Chronic Graft Versus Host Disease

Rare Disease Report

Frontline management of chronic GvHD

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Jacobs on Treating Graft-Versus-Host-Disease With Ibrutinib in CLL

Introduction to Chronic Graft versus Host Disease 2020

Limitations of ibrutinib and ruxolitinib use in cGVHD

VJHemOnc – Video Journal of Hematology & HemOnc

David Miklos, MD, PhD, explains how ibrutinib is being studied for the treatment of GVHD

Understanding the biology of chronic GvHD

VJHemOnc – Video Journal of Hematology & HemOnc

Mechanisms of action of ibrutinib, ruxolitinib, and belumosudil, and their role in cGvHD treatment

Advances in the prevention and treatment of GvHD

VJHemOnc – Video Journal of Hematology & HemOnc

Despite toxicities, ibrutinib is beneficial for treatment-resistant graft-vs.-host disease

MDedge: news and insights for busy physicians

Introduction to Chronic Graft-vs-Host Disease (GVHD) 2018

David Miklos, MD, PhD, describes the optimal way to use ibrutinib in the treatment of GVHD

Overcoming GVHD Is the Key to Better HCT Outcomes: Guidance on Managing Acute and Chronic Disease

PeerView Oncology

INTEGRATE: 2-year follow-up of ibrutinib plus corticosteroids for cGvHD

VJHemOnc – Video Journal of Hematology & HemOnc

David Miklos, MD, discusses the outcomes in the phase 2 ibrutinib study for chronic GvHD

Ibrutinib, ruxolitinib & belumosudil for SR-cGvHD

VJHemOnc – Video Journal of Hematology & HemOnc